Form 4: Protalix Director Awarded Shares & Options

Protalix BioTherapeutics director Shmuel Ben Zvi received an award of 7,500 restricted common shares and 15,000 stock options.

Summary

• Director Shmuel Ben Zvi was awarded 7,500 restricted shares of Protalix BioTherapeutics, Inc. common stock on September 3, 2025.
• The restricted shares were granted under the company's Amended and Restated 2006 Stock Incentive Plan and will vest in 12 equal quarterly installments commencing upon the date of grant.
• Additionally, Mr. Ben Zvi received 15,000 stock options with an exercise price of $1.64 per share, also granted on September 3, 2025, and expiring on September 3, 2035.
• These stock options will also vest in 12 equal quarterly installments commencing on the grant date.
• The restricted shares are held indirectly by a trust to qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance.

Sentiment

Score: 7

Explanation: The filing indicates routine equity compensation for a director, which is generally a positive sign of continued commitment and alignment of interests, without any negative surprises.

Positives

• Increased alignment of a director's interests with shareholders through equity awards.
• The awards demonstrate continued commitment and incentivization for key management personnel.

Negatives

• Potential for future share dilution upon vesting and exercise of options, though this is a standard aspect of equity compensation.

Future Outlook

The equity awards are structured to vest over three years, indicating a long-term incentive for the director's continued service and alignment with future company performance.

Industry Context

Equity compensation for directors, including restricted stock and stock options, is a standard practice across the biotechnology and pharmaceutical industries to attract and retain talent, align interests with shareholders, and incentivize long-term performance. The vesting schedule over multiple quarters is typical for such awards.

Comparison to Industry Standards

• The structure of these equity awards, with a multi-year vesting schedule and a combination of restricted stock and options, is consistent with common compensation practices for non-executive directors in the biotechnology sector.
• Similar plans are observed at companies like BioNTech or Moderna, where director compensation often includes a significant equity component to foster long-term commitment and performance alignment.
• The exercise price of $1.64 for the options is set at the market price on the grant date, which is standard practice for such awards.

Corporate Governance

Related Party Transactions

• The transaction involves equity awards to a director, Shmuel Ben Zvi, which is a related party transaction as part of their compensation package.

Stakeholder Impact

• Shareholders: Potential for minor dilution from future share issuance upon vesting and exercise, but also increased alignment of director's interests with long-term shareholder value.

Next Steps

• The restricted shares and stock options will vest in 12 equal quarterly installments commencing on September 3, 2025.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation for a director, which is a standard practice to align management interests with shareholders. It does not present new information that would fundamentally alter the investment thesis for Protalix BioTherapeutics, nor does it indicate any significant operational or financial changes. Therefore, a 'hold' recommendation is appropriate as it neither provides a strong catalyst for a 'buy' nor a significant negative for a 'sell'.

Keywords

Protalix BioTherapeutics, PLX, SEC Form 4, Insider Trading, Stock Options, Restricted Stock, Equity Compensation, Director Compensation, Shmuel Ben Zvi